Inclusion Criteria:  Age ≥18 years and ≤70 years; ECOG physical condition score: 0~1; Clinical/pathological diagnosis of primary liver cancer or intrahepatic metastatic colorectal cancer; Clinical evaluation requires (extended) hemihepatectomy; Liver function Child A level sFLR < 30%  The main organs function well, and the examination indicators meet the following requirements:  Routine blood tests:  Hemoglobin ≥90 g/L (no blood transfusion within 14 days); Neutrophil count ≥1.5×10^9/L; Platelet count ≥80×10^9/L;  Biochemical examination:  Total bilirubin ≤2×ULN (upper normal value); ALT or AST ≤ 2.5×ULN; Endogenous creatinine clearance ≥ 50 mL /min (Cockcroft-Gault formula);  Sign the informed consent voluntarily; Good compliance, and family members willing to cooperate with follow-up.  Exclusion Criteria:  Presence of extrahepatic organ/distant lymph node metastasis; Hilar lymph node metastasis cannot be radically resected; Patients with intrahepatic metastatic colorectal cancer had received second-line or above systemic therapy; Other uncured malignant tumors; Pregnant or lactating women who are pregnant during the study period need to withdraw from the clinical trial; Concurrent use of any other antitumor therapy in patients with primary liver cancer; Patients with intrahepatic metastatic colorectal cancer have been treated with antitumor therapy in addition to primary surgery and standard first-line/second-line therapy; Patients with a known history of other systemic serious diseases before screening; Long-term unhealed wounds or incomplete healing fractures; Previous organ transplantation history; Having a history of abuse of psychotropic substances and being unable to quit or having mental disorders; A history of immune deficiency or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation; Concomitant conditions that, in the investigator's judgment, seriously endanger the patient's safety or affect the patient's completion of the study.